XTX Topco Ltd Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

XTX Topco Ltd increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 294.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 30,022 shares of the company's stock after purchasing an additional 22,402 shares during the quarter. XTX Topco Ltd's holdings in CRISPR Therapeutics were worth $1,410,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Larson Financial Group LLC boosted its holdings in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company's stock valued at $31,000 after purchasing an additional 276 shares during the period. GPS Wealth Strategies Group LLC lifted its holdings in shares of CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company's stock worth $33,000 after buying an additional 307 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth $35,000. Darwin Wealth Management LLC bought a new position in shares of CRISPR Therapeutics during the 3rd quarter worth $43,000. Finally, Denver PWM LLC purchased a new position in shares of CRISPR Therapeutics during the second quarter valued at $45,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on CRSP shares. Barclays lowered their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a research note on Wednesday, November 6th. Needham & Company LLC reissued a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research report on Thursday, November 7th. Finally, Truist Financial reduced their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating for the company in a research report on Monday, August 12th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $74.94.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock worth $2,744,179 over the last quarter. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Price Performance

CRSP traded down $2.49 during trading on Monday, reaching $49.84. 2,053,731 shares of the company's stock were exchanged, compared to its average volume of 1,498,799. The company's fifty day simple moving average is $48.71 and its 200-day simple moving average is $51.40. The stock has a market capitalization of $4.25 billion, a P/E ratio of -17.61 and a beta of 1.62. CRISPR Therapeutics AG has a 1 year low of $43.42 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the previous year, the firm posted ($1.41) earnings per share. Equities analysts forecast that CRISPR Therapeutics AG will post -5.17 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.